Retinal Biologics Market
Market Insights on Retinal Biologics covering sales outlook, demand forecast & up-to-date key trends
Retinal Biologics Market By Drug Class (VEGF-A Antagonists, TNF-A Inhibitors), Indication (Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Uveitis) & Region - Forecast 2022 - 2028
Retinal Biologics Market Outlook (2022-2028)
[194 Pages Report] Retinal biologics market revenue totaled US$ 19.96 Bn in 2021. The global market is expected to reach US$ 41.92 Bn by 2028, surging at a CAGR of 11.1% over the period of 2022-2028.
|
Retinal Biologics Market Size (2022) |
US$ 22.25 Bn |
|
Sales Forecast (2028) |
US$ 41.92 Bn |
|
Global Market Growth Rate (2022 to 2028) |
11.1% CAGR |
|
Share of Top 5 Players |
50% |
Retinal biologics accounted for 6.9% share of the global biologic therapeutics market in 2021.
Let us know your requirement to get
100% FREE customization
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
11.08% |
|
H1, 2022 Projected |
11.14% |
|
H1, 2022 Outlook |
10.94% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 20 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 14 ↓ |
According to Future Market Insights' analysis, the global retinal biologics market expects to drop by 14 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 Projected value, the market during H1-2022 outlook period will show a dip of 20 BPS.
The availability of very few retinal biologics, their severe side effects, rigorous regulatory standards involved with obtaining biologics approvals, and the exorbitant cost of effective drugs and biologics are all contributing factors to the drop in BPS values.
The market will however witness a positive growth outlook over the forecast period, owed to the increasing intensive research activities for the production of novel biologics for novel disease therapeutics.
The key development in the market includes innovations in ocular drug delivery to the retina with the development of intravitreal drugs. The retinal biologics market is subject to macroeconomic and industrial factors in accordance to stringent regulatory standards and approval activities for biologics.
Demand Analysis Of Retinal Biologics From 2013-2021 Vs Future Market Outlook For 2022-2028
“Rising Burden of Retinal Diseases to Boost Overall Market Growth”
From 2013 to 2021, the global retinal biologics market registered significant gains, experiencing a CAGR worth 10.2%
Retinal biologics are bioengineered molecules that are implanted inside the eyes to heal chronic retinal diseases. Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Some of the retinal biologics used for retinal diseases are Eylea, Lucentis, Humira, Macugen, and others.
Increased frequency of retinal diseases such as age-related macular degeneration around the world is driving the market expansion. According to WHO statistics, nearly 2.2 billion individuals worldwide suffer from near or distance vision impairment. As the prevalence of vision impairment rises, the need for effective therapeutic alternatives, such as retinal biologics, is rising as well.
Retinal biologics are a new class of medications that target specific markers in the patient's body to alleviate the symptoms of a variety of systemic or ocular disorders that present in the eye.
Considering these factors, the market is projected to witness high growth over the forecast period, registering an impressive CAGR of 11.1% to reach US$ 41.92 Bn by 2028.
What Are The Major Factors Driving Retinal Biologics Market Growth?
“Rising R&D Activities in Retinal Gene Therapies to Fuel Market Expansion”
The market will be driven by a strong focus on R&D connected with retinal gene therapies conducted by different institutes, biologics firms, and innovative product releases by prominent market participants in the form of biologics and implants. Efforts to develop a complementary therapeutic treatment will boost the market growth.
“Market Growth Complemented by Increasing Burden of Retinal Diseases”
Diabetic retinopathy has been a rising concern as the disease leads to vision loss among type I and type II adult diabetic patients. Diabetic macular edema also results from the consequences of diabetic retinopathy, which leads to the swelling of the macula. Moreover, increasing burden of other retinal diseases such as uveitis and orbital inflammation is another factor surging demand for retinal drugs and biologics.
Retinal gene therapy is a therapeutic approach wherein inherited defective genes are replaced by treatment with DNA or RNA. Retinal gene therapy is considered to be a significant approach as there occurs less contamination, and the viral vector can easily accommodate within the eyes.
What Are The Key Restraints Towards The Retinal Biologics Market Growth?
“Regulatory Obstructions Likely to Hinder Demand for Retinal Biologics”
Limited availability of retinal biologics, hazardous biologic side effects, and limited access for retinal biologics and efficient treatments due to higher costs are restraining the market growth.
The market is being challenged by the side effects of retinal biologics, which include retinal tear, sickness, and eye pain. Governing authorities' strict regulatory compliances associated with biologics approval are impeding industry growth.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow Is North America Propelling Demand For Retinal Biologics?
“Ongoing Advancements in Biologics for Retinal Treatment”
North America is expected to have a significant share in the global retinal biologics market. Continuous improvements in healthcare infrastructure, as well as an increase in the number of cases of retinal illnesses and favorable reimbursement policies, are expected to promote market expansion in the region.
Prominent presence of key manufacturers and increased healthcare spending are driving market growth in the region. Growing diabetes population is a major driver in the development of biologics for retinal treatment in North America.
Country-Wise Analysis
Why is the U.S. Retinal Biologics Market Growing at a Rapid Pace?
“Increased Prevalence of Diabetic Macular Edema to Augment Demand for Retinal Biologics”
Diabetic retinopathy is a disease that affects people who have diabetes. Diabetic retinopathy is the major cause of new incidents of blindness in adults aged 20 to 74 years in the United States.
According to a new research study released by the Centers for Disease Control and Prevention, more than 100 million persons in the United States currently have diabetes or prediabetes.
In addition, researchers are working on innovative strategies to treat diabetic macular edema. As a result, rising R&D spending in the country as well as risk factors that contribute to disease development will have an impact on the retinal biologics market in the U.S. over the forecast period.
What is the Demand Outlook for Retinal Biologics in China?
“Rising Efforts for Development of Retinal Drugs to Drive Market Growth.”
The market in China is expected to grow due to rapidly rising cases of uveitis, diabetic retinopathy, and macular degeneration. Diabetes is exacerbated by a shift in lifestyle and an increase in bad eating habits, as a result of these factors, the global market for retinal drugs and biologics is expected to expand significantly.
Along with increasing incidence of eye diseases, there are a growing number of research initiatives focused on retinal drugs. Furthermore, growing geriatric population, which is becoming a target patient pool for retinal biologics, will boost market growth in China.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-Wise Insights
Which Drug Class is Projected to Get Traction in Retinal Biologics?
“VEGF-A Antagonists Most Preferred as They are Largely Tolerated & Give Instant Results to Eye Disorders.”
VEGF-A antagonists are used to treat eye damage and enhance corneal wound healing. The global retinal biologics market is also expected to be fueled by the rising prevalence of other retinal illnesses such as orbital inflammation and uveitis.
VEGF-A antagonists are commonly given for the treatment of diabetic retinopathy and diabetic macular edema. In the case of non-infectious uveitis, it is seen to be the ideal alternative to typical suppressing treatments.
Many firms have focused on VEGF-A antagonists because they reduce angiogenesis. Manufacturers are investing in the development of retinal biologics in a similar field due to the widespread acceptance of VEGF-A antagonist therapy.
Which Indication Dominates Retinal Biologics Demand Growth?
“Increasing Adoption of Retinal Biologics for Macular Degeneration Treatment”
Macular degeneration indication is expected to account 36.9% share of the retinal biologics market in 2022. Macular Degeneration is a vision loss condition that affects the macula.
Despite the availability of improved treatment alternatives, the global retinal biologics market is likely to benefit from the increased prevalence of macular degeneration. According to the American Macular Degeneration Foundation, the prevalence is higher than the combined rates of cataracts and glaucoma in over 10 million Americans (AMDF).
Because macular degeneration primarily affects adults aged 50 and over, the prevalence of MD continues to go up, despite improving treatment choices, as the population ages.
COVID-19 Impact On Market Expansion
The COVID-19 pandemic has had a massive effect on the worldwide healthcare system, resulting in a decreased focus on retinal biologics. The COVID-19 pandemic has disrupted global care patterns and prompted broad modifications in disease management across a wide range of therapeutic disciplines. Ophthalmology was one of the first areas to be affected.
The retinal biologics industry is expected to recover soon, owing to an increase in research efforts and significant government support. The importance of treatments and disease control protocols may increase demand for retinal biologics over the coming years
Competitive Landscape
Several companies are entering into licensing and collaboration agreements to expand their products into various countries across the world to cater to unmet demand. Leading market players are concentrating their efforts on research & development to discover new medications and improve treatment options.
For instance,
- In 2021, SemaThera Inc. and Roche established a multi-year research and licensing relationship to expand SemaThera's novel biologics portfolio for the treatment of ischemic retinal illnesses such as diabetic retinopathy.
Retinal Biologics Industry Report Scope
|
Attribute |
Details |
|
Forecast Period |
2022-2028 |
|
Historical Data Available for |
2013-2021 |
|
Market Analysis |
Value in US$ Mn |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Segments of Retinal Biologics Industry Survey
Retinal Biologics Market by Drug Class:
- VEGF-A Antagonists
- TNF-α Inhibitors
Retinal Biologics Market by Indication:
- Macular Degeneration
- Diabetic Macular Edema
- Diabetic Retinopathy
- Uveitis
- Others
Retinal Biologics Market by Distribution Channel:
- Institutional Sales
- Retail Pharmacies
- Mail Order Pharmacies
- Retail Sales
Retinal Biologics Market by Region:
- North America Retinal Biologics Market
- Latin America Retinal Biologics Market
- Europe Retinal Biologics Market
- East Asia Retinal Biologics Market
- South Asia & Pacific Retinal Biologics Market
- Middle East & Africa (MEA) Retinal Biologics Market
Frequently Asked Questions
The global retinal biologics market is estimated to exhibit a CAGR of 11.1% during the forecast period (2022-2028).
Macular degeneration accounts for 36.9% share of the retinal biologics market.
The global retinal biologics market is expected to reach a valuation of US$ 41.92 Bn by 2028.
Increasing prevalence of diabetic eye diseases and significant R&D investments for developing biologics are key trends driving market growth.
Major players operating in the market include Spark Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals, Inc., AbbVie Inc., and Amgen Inc.
Table of Content
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Global Economic Outlook
3.1. Gross Domestic Indication Type by Region & Country, 2006 – 2021
3.2. Global Healthcare Market Indicators
4. Market Opportunity Analysis
4.1. Macro-Economic Factors
4.2. Opportunity Analysis
5. Market Dynamics
5.1. Drivers
5.1.1. Supply Side Drivers
5.1.2. Demand Side Drivers
5.2. Restraints
5.3. Trends
6. Key Inclusion
6.1. Key Regulations
6.2. Reimbursement Scenario
6.3. Pricing Analysis
7. North America Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028
7.1. Introduction
7.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
7.2.1. U.S.
7.2.2. Canada
7.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
7.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
7.4.1. VEGF-An antagonist
7.4.2. TNF-α inhibitor
7.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
7.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
7.6.1. Macular Degeneration
7.6.2. Diabetic Retinopathy
7.6.3. Diabetic Macular Edema
7.6.4. Uveitis
7.6.5. Others
7.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
7.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021
7.8.1. Institutional Sales
7.8.1.1. Specialty Clinics
7.8.1.2. Hospitals
7.8.2. Retail Sales
7.8.2.1. Retail Pharmacies
7.8.2.2. Mail Order Pharmacies
7.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
7.10. Market Attractiveness Analysis
7.10.1. By Country
7.10.2. By Drug Class
7.10.3. By Indication
7.10.4. By Distributional Channel
7.11. Drivers and Restraints: Impact Analysis
7.12. Key Market Participants – Intensity Mapping
8. Latin America Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028
8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
8.3.1. Brazil
8.3.2. Mexico
8.3.3. Argentina
8.3.4. Rest of Latin America
8.4. Market Size (US$ Mn) Forecast By Country, 2022-2028
8.5. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
8.5.1. VEGF-A antagonist
8.5.2. TNF-α inhibitor
8.6. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
8.7. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
8.7.1. Macular Degeneration
8.7.2. Diabetic Retinopathy
8.7.3. Diabetic Macular Edema
8.7.4. Uveitis
8.7.5. Others
8.8. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
8.9. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021
8.9.1. Institutional Sales
8.9.1.1. Specialty Clinics
8.9.1.2. Hospitals
8.9.2. Retail Sales
8.9.2.1. Retail Pharmacies
8.9.2.2. Mail Order Pharmacies
8.10. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
8.11. Market Attractiveness Analysis
8.11.1. By Country
8.11.2. By Drug Class
8.11.3. By Indication
8.11.4. By Distributional Channel
8.12. Drivers and Restraints: Impact Analysis
8.13. Key Market Participants – Intensity Mapping
9. Western Europe Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028
9.1. Introduction
9.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
9.2.1. Germany
9.2.2. U.K
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Western Europe
9.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
9.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
9.4.1. VEGF-A antagonist
9.4.2. TNF-α inhibitor
9.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
9.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
9.6.1. Macular degeneration
9.6.2. Diabetic Retinopathy
9.6.3. Diabetic Macular Edema
9.6.4. Uveitis
9.6.5. Others
9.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
9.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021
9.8.1. Institutional Sales
9.8.1.1. Specialty Clinics
9.8.1.2. Hospitals
9.8.2. Retail Sales
9.8.2.1. Retail Pharmacies
9.8.2.2. Mail Order Pharmacies
9.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
9.10. Market Attractiveness Analysis
9.10.1. By Country
9.10.2. By Drug Class
9.10.3. By Indication
9.10.4. By Distributional Channel
9.11. Drivers and Restraints: Impact Analysis
9.12. Key Market Participants – Intensity Mapping
10. Eastern Europe Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
10.2.1. Russia
10.2.2. Poland
10.2.3. Rest of Eastern Europe
10.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
10.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
10.4.1. VEGF-A antagonist
10.4.2. TNF-α inhibitor
10.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
10.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
10.6.1. Macular degeneration
10.6.2. Diabetic Retinopathy
10.6.3. Diabetic Macular Edema
10.6.4. Uveitis
10.6.5. Others
10.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
10.8. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021
10.8.1. Institutional Sales
10.8.1.1. Specialty Clinics
10.8.1.2. Hospitals
10.8.2. Retail Sales
10.8.2.1. Retail Pharmacies
10.8.2.2. Mail Order Pharmacies
10.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
10.10. Market Attractiveness Analysis
10.10.1. By Country
10.10.2. By Drug Class
10.10.3. By Indication
10.10.4. By Distributional Channel
10.11. Drivers and Restraints: Impact Analysis
10.12. Key Market Participants – Intensity Mapping
11. Asia Pacific Excluding Japan Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
11.2.1. China
11.2.2. India
11.2.3. Australia and New Zealand
11.2.4. ASEAN
11.2.5. Rest of APEJ
11.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
11.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
11.4.1. VEGF-A antagonist
11.4.2. TNF-α inhibitor
11.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
11.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
11.6.1. Macular degeneration
11.6.2. Diabetic Retinopathy
11.6.3. Diabetic Macular Edema
11.6.4. Uveitis
11.6.5. Others
11.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
11.8. Historical Market Size (US$ Mn) and Trend Analysis by Distributional Channel, 2013-2021
11.8.1. Institutional Sales
11.8.1.1. Specialty Clinics
11.8.1.2. Hospitals
11.8.2. Retail Sales
11.8.2.1. Retail Pharmacies
11.8.2.2. Mail Order Pharmacies
11.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
11.10. Market Attractiveness Analysis
11.10.1. By Country
11.10.2. By Drug Class
11.10.3. By Indication
11.10.4. By Distributional Channel
11.11. Drivers and Restraints: Impact Analysis
11.12. Key Market Participants – Intensity Mapping
12. Japan Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028
12.1. Introduction
12.2. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
12.2.1. VEGF-A antagonist
12.2.2. TNF-α inhibitor
12.3. Market Size (US$ Mn) and Forecast By Drug Class, 2022-2028
12.4. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
12.4.1. Macular degeneration
12.4.2. Diabetic Retinopathy
12.4.3. Diabetic Macular Edema
12.4.4. Uveitis
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast By Indication, 2022-2028
12.6. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021
12.6.1. Institutional Sales
12.6.1.1. Specialty Clinics
12.6.1.2. Hospitals
12.6.2. Retail Sales
12.6.2.1. Retail Pharmacies
12.6.2.2. Mail Order Pharmacies
12.7. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
12.8. Market Attractiveness Analysis
12.8.1. By Drug Class
12.8.2. By Indication
12.8.3. By Distributional Channel
12.9. Drivers and Restraints: Impact Analysis
12.10. Key Market Participants – Intensity Mapping
13. Middle East and Africa Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis by Country, 2013-2021
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Rest of Middle East and Africa
13.3. Market Size (US$ Mn) Forecast By Country, 2022-2028
13.4. Historical Market Size (US$ Mn) and Trend Analysis by Drug Class, 2013-2021
13.4.1. VEGF-A antagonist
13.4.2. TNF-α inhibitor
13.5. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
13.6. Historical Market Size (US$ Mn) and Trend Analysis by Indication, 2013-2021
13.6.1. Macular degeneration
13.6.2. Diabetic Retinopathy
13.6.3. Diabetic Macular Edema
13.6.4. Uveitis
13.6.5. Others
13.7. Market Size (US$ Mn) and Forecast By Indication, 2022-2028
13.8. Historical Market Size (US$ Mn) Trend Analysis by Distributional Channel, 2013-2021
13.8.1. Institutional Sales
13.8.1.1. Specialty Clinics
13.8.1.2. Hospitals
13.8.2. Retail Sales
13.8.2.1. Retail Pharmacies
13.8.2.2. Mail Order Pharmacies
13.9. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
13.10. Market Attractiveness Analysis
13.10.1. By Country
13.10.2. By Drug Class
13.10.3. By Indication
13.10.4. By Distributional Channel
13.11. Drivers and Restraints: Impact Analysis
13.12. Key Market Participants – Intensity Mapping
14. Forecast Factors: Relevance and Impact
15. Forecast Assumptions
16. Competition Analysis
16.1. Competition Dashboard
16.2. Competitors Deep Dive
16.2.1. Spark Therapeutics Inc.
16.2.1.1. Overview
16.2.1.2. Key Financials
16.2.1.3. SWOT Analysis
16.2.1.4. Key Developments
16.2.1.5. Key Strategy
16.2.2. F. Hoffmann-La Roche Ltd
16.2.2.1. Overview
16.2.2.2. Key Financials
16.2.2.3. SWOT Analysis
16.2.2.4. Key Developments
16.2.2.5. Key Strategy
16.2.3. Regeneron Pharmaceuticals, Inc.
16.2.3.1. Overview
16.2.3.2. Key Financials
16.2.3.3. SWOT Analysis
16.2.3.4. Key Developments
16.2.3.5. Key Strategy
16.2.4. AbbVie Inc
16.2.4.1. Overview
16.2.4.2. Key Financials
16.2.4.3. SWOT Analysis
16.2.4.4. Key Developments
16.2.4.5. Key Strategy
16.2.5. Johnson & Johnson Services, Inc
16.2.5.1. Overview
16.2.5.2. Key Financials
16.2.5.3. SWOT Analysis
16.2.5.4. Key Developments
16.2.5.5. Key Strategy
16.2.6. Amgen Inc.
16.2.6.1. Overview
16.2.6.2. Key Financials
16.2.6.3. SWOT Analysis
16.2.6.4. Key Developments
16.2.6.5. Key Strategy
17. Global Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028 by Region
17.1. Introduction / Key Findings
17.2. Historical Market Size (US$ Mn) Analysis by Region
17.2.1. North America
17.2.2. Latin America
17.2.3. Western Europe
17.2.4. Eastern Europe
17.2.5. Asia Pacific Excluding Japan
17.2.6. Japan
17.2.7. Middle East and Africa
17.3. Market Size (US$ Mn) Forecast By Region
17.4. Market Attractiveness Analysis by Region
18. Global Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
18.1. Introduction/Key Finding
18.2. Historical Market Size (US$ Mn) Analysis by Drug Class, 2013-2021
18.2.1. VEGF-A antagonist
18.2.2. TNF-α inhibitor
18.3. Market Size (US$ Mn) Forecast By Drug Class, 2022-2028
18.4. Market Attractiveness Analysis by Drug Class
19. Global Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028, By Indication
19.1. Introduction/Key Finding
19.2. Historical Market Size (US$ Mn) Analysis by Indication, 2013-2021
19.2.1. Macular degeneration
19.2.2. Diabetic Retinopathy
19.2.3. Diabetic Macular Edema
19.2.4. Uveitis
19.2.5. Others
19.3. Market Size (US$ Mn) Forecast By Indication, 2022-2028
19.4. Market Attractiveness Analysis by Indication
20. Global Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028, By Distributional Channel
20.1. Introduction/Key Finding
20.2. Historical Market Size (US$ Mn) Analysis by Distributional Channel, 2013-2021
20.2.1. Institutional Sales
20.2.1.1. Specialty Clinics
20.2.1.2. Hospitals
20.2.2. Retail Sales
20.2.2.1. Retail Pharmacies
20.2.2.2. Mail Order Pharmacies
20.3. Market Size (US$ Mn) Forecast By Distributional Channel, 2022-2028
20.4. Market Attractiveness Analysis by Distributional Channel
21. Global Retinal Biologics Market Analysis 2013–2021 and Forecast 2022–2028
21.1. Global Market Value Analysis (US$ Mn)
21.2. Absolute $ Opportunity
22. Assumptions and Acronyms Used
23. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Expenditure on Health, (% of GDP), by Country, 2013 - 2021
Table 02: Expenditure on Health, (% of GDP), by Country, 2013 - 2021
Table 03: North America Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 04: North America Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 05: North America Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 06: North America Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 07: Latin America Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 08: Latin America Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 09: Latin America Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 10: Latin America Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 11: Western Europe Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 12: Western Europe Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 13: Western Europe Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 14: Western Europe Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 15: Eastern Europe Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 16: Eastern Europe Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 17: Eastern Europe Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 18: Eastern Europe Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 19: Asia Pacific Excluding Japan Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 20: Asia Pacific Excluding Japan Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 21: Asia Pacific Excluding Japan Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 22: Asia Pacific Excluding Japan Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 23: Japan Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 24: Japan Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 25: Japan Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 26: Middle East and Africa Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Country
Table 27: Middle East and Africa Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 28: Middle East and Africa Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 29: Middle East and Africa Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Table 30: Global Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region
Table 31: Global Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Table 32: Global Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Table 33: Global Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Retinal Biologics Market Value (US$ Mn), by Regions
Figure 2: Global Retinal Biologics Market Value Share By Drug Class (2021)
Figure 3: Global Retinal Biologics Market Value Share By Indication (2021)
Figure 4: Global Retinal Biologics Market Value Share By Distributional Channel
Figure 5: Global Healthcare Expenditure in US$ Tn (2013–2021)
Figure 6: North America Retinal Biologics Market Size (US$ Mn) Analysis, 2013–2021
Figure 7: North America Retinal Biologics Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 8: North America Retinal Biologics Market Analysis by Country –2022 & 2028
Figure 9: North America Retinal Biologics Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 10: North America Retinal Biologics Market Attractiveness Analysis by Country, 2022 – 2028
Figure 11: North America Retinal Biologics Market Analysis by Drug Class–2022 & 2028
Figure 12: North America Retinal Biologics Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 13: North America Retinal Biologics Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 14: North America Retinal Biologics Market Analysis by Indication–2022 & 2028
Figure 15: North America Retinal Biologics Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 16: North America Retinal Biologics Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 17: North America Retinal Biologics Market Analysis by Distribution Channel–2022 & 2028
Figure 18: North America Retinal Biologics Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 19: North America Retinal Biologics Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 20: Latin America Retinal Biologics Market Size (US$ Mn) Analysis, 2013–2021
Figure 21: Latin America Retinal Biologics Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 22: Latin America Retinal Biologics Market Analysis by Country –2022 & 2028
Figure 23: Latin America Retinal Biologics Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 24: Latin America Retinal Biologics Market Attractiveness Analysis by Country, 2022 – 2028
Figure 25: Latin America Retinal Biologics Market Analysis by Drug Class–2022 & 2028
Figure 26: Latin America Retinal Biologics Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 27: Latin America Retinal Biologics Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 28: Latin America Retinal Biologics Market Analysis by Indication–2022 & 2028
Figure 29: Latin America Retinal Biologics Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 30: Latin America Retinal Biologics Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 31: Latin America Retinal Biologics Market Analysis by Distribution Channel–2022 & 2028
Figure 32: Latin America Retinal Biologics Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 33: Latin America Retinal Biologics Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 34: Western Europe Retinal Biologics Market Size (US$ Mn) Analysis, 2013–2021
Figure 35: Western Europe Retinal Biologics Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 36: Western Europe Retinal Biologics Market Analysis by Country –2022 & 2028
Figure 37: Western Europe Retinal Biologics Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 38: Western Europe Retinal Biologics Market Attractiveness Analysis by Country, 2022 – 2028
Figure 39: Western Europe Retinal Biologics Market Analysis by Drug Class–2022 & 2028
Figure 40: Western Europe Retinal Biologics Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 41: Western Europe Retinal Biologics Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 42: Western Europe Retinal Biologics Market Analysis by Indication–2022 & 2028
Figure 43: Western Europe Retinal Biologics Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 44: Western Europe Retinal Biologics Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 45: Western Europe Retinal Biologics Market Analysis by Distribution Channel–2022 & 2028
Figure 46: Western Europe Retinal Biologics Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 47: Western Europe Retinal Biologics Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 48: Eastern Europe Retinal Biologics Market Size (US$ Mn) Analysis, 2013–2021
Figure 49: Eastern Europe Retinal Biologics Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 50: Eastern Europe Retinal Biologics Market Analysis by Country –2022 & 2028
Figure 51: Eastern Europe Retinal Biologics Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 52: Eastern Europe Retinal Biologics Market Attractiveness Analysis by Country, 2022 – 2028
Figure 53: Eastern Europe Retinal Biologics Market Analysis by Drug Class–2022 & 2028
Figure 54: Eastern Europe Retinal Biologics Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 55: Eastern Europe Retinal Biologics Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 56: Eastern Europe Retinal Biologics Market Analysis by Indication–2022 & 2028
Figure 57: Eastern Europe Retinal Biologics Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 58: Eastern Europe Retinal Biologics Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 59: Eastern Europe Retinal Biologics Market Analysis by Distribution Channel–2022 & 2028
Figure 60: Eastern Europe Retinal Biologics Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 61: Eastern Europe Retinal Biologics Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 62: Asia Pacific Excluding Japan Retinal Biologics Market Size (US$ Mn) Analysis, 2013–2021
Figure 63: Asia Pacific Excluding Japan Retinal Biologics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 64: Asia Pacific Excluding Japan Retinal Biologics Market Analysis by Country –2022 & 2028
Figure 65: Asia Pacific Excluding Japan Retinal Biologics Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 66: Asia Pacific Excluding Japan Retinal Biologics Market Attractiveness Analysis by Country, 2022 – 2028
Figure 67: Asia Pacific Excluding Japan Retinal Biologics Market Analysis by Drug Class–2022 & 2028
Figure 68: Asia Pacific Excluding Japan Retinal Biologics Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 69: Asia Pacific Excluding Japan Retinal Biologics Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 70: Asia Pacific Excluding Japan Retinal Biologics Market Analysis by Indication–2022 & 2028
Figure 71: Asia Pacific Excluding Japan Retinal Biologics Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 72: Asia Pacific Excluding Japan Retinal Biologics Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 73: Asia Pacific Excluding Japan Retinal Biologics Market Analysis by Distribution Channel–2022 & 2028
Figure 74: Asia Pacific Excluding Japan Retinal Biologics Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 75: Asia Pacific Excluding Japan Retinal Biologics Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 76: Japan Retinal Biologics Market Size (US$ Mn) Analysis, 2013–2021
Figure 77: Japan Retinal Biologics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 78: Japan Retinal Biologics Market Analysis by Drug Class–2022 & 2028
Figure 79: Japan Retinal Biologics Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 80: Japan Retinal Biologics Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 81: Japan Retinal Biologics Market Analysis by Indication–2022 & 2028
Figure 82: Japan Retinal Biologics Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 83: Japan Retinal Biologics Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 84: Japan Retinal Biologics Market Analysis by Distribution Channel–2022 & 2028
Figure 85: Japan Retinal Biologics Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 86: Japan Retinal Biologics Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 87: Middle East and Africa Retinal Biologics Market Size (US$ Mn) Analysis, 2013–2021
Figure 88: Middle East and Africa Retinal Biologics Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 89: Middle East and Africa Retinal Biologics Market Analysis by Country –2022 & 2028
Figure 90: Middle East and Africa Retinal Biologics Market Y-o-Y Growth Projections by Country, 2022 – 2028
Figure 91: Middle East and Africa Retinal Biologics Market Attractiveness Analysis by Country, 2022 – 2028
Figure 92: Middle East and Africa Retinal Biologics Market Analysis by Drug Class–2022 & 2028
Figure 93: Middle East and Africa Retinal Biologics Market Y-o-Y Growth Projections by Drug Class, 2022 – 2028
Figure 94: Middle East and Africa Retinal Biologics Market Attractiveness Analysis by Drug Class, 2022 – 2028
Figure 95: Middle East and Africa Retinal Biologics Market Analysis by Indication–2022 & 2028
Figure 96: Middle East and Africa Retinal Biologics Market Y-o-Y Growth Projections by Indication, 2022 – 2028
Figure 97: Middle East and Africa Retinal Biologics Market Attractiveness Analysis by Indication, 2022 – 2028
Figure 98: Middle East and Africa Retinal Biologics Market Analysis by Distribution Channel–2022 & 2028
Figure 99: Middle East and Africa Retinal Biologics Market Y-o-Y Growth Projections by Distribution Channel, 2022 – 2028
Figure 100: Middle East and Africa Retinal Biologics Market Attractiveness Analysis by Distribution Channel, 2022 – 2028
Figure 101: Global Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Region
Figure 102: Global Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Drug Class
Figure 103: Global Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Indication
Figure 104: Global Retinal Biologics Market Size (US$ Mn) Analysis 2013-2021 and Forecast 2022-2028, By Distribution Channel
Figure 105: Global Retinal Biologics Market Size (US$ Mn) Analysis, 2013–2021
Figure 106: Global Retinal Biologics Market Size (US$ Mn) & Y-o-Y Growth (%),
Figure 107: Global Retinal Biologics Market Absolute $ Opportunity, 2013–2028
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
